Tradjenta, also known as Trajenta in Canada, which is a DPP-4 (dipeptidyl peptidase-4) inhibitor used to treat type 2 diabetes. Tradjenta has been approved by the U.S. Food and Drug Administration to improve blood sugar control in people with type 2 diabetes together with the diet and exercise.

Linagliptin works by blocking the DPP-4 for raising the levels of insulin-stimulating hormones in the body. It can be used on its own or together with metformin, sulfonylurea or pioglitazone.

The most common side effects of Tradjenta were headache, muscle pain, respiratory infection, and sore throat. Take Tradjenta 5 mg tablet once a daily. People with kidney or liver problems do not need to adjust the dose of Tradjenta.

Tradjenta is the new DPP-4 inhibitor will compete with two other drugs in the same class: buy Januvia, buy Onglyza